DRUG · Unmapped registry intervention
LB-102
Find medicine records ·
Find other trials using this name
Clinical trial
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
NCT06179108
Study summary
ClinicalTrials.govRandomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Advertisement
Conditions
Schizophreniaverified · MONDO: schizophrenia
Interventions
LB-102DRUG
Sponsors & collaborators
LB Pharmaceuticals Inc.lead sponsor
Mapped research locations
ChicagoIllinois, United States2HollywoodFlorida, United States2AtlantaGeorgia, United States1AustinTexas, United States1Little RockArkansas, United States1DaytonOhio, United States1DecaturGeorgia, United States1RiversideCalifornia, United States1Staten IslandNew York, United States1Santa AnaCalifornia, United States1Garden GroveCalifornia, United States1Miami LakesFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06179108 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.